Stockreport

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yaho...

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF ENHERTU now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers WILMINGTON, Del., April 06, 2024 BUSINESS WIRE )--AstraZeneca [Read more]